dr_jean-michel_cossery_photo

New managing director for Lilly UK

pharmafile | December 12, 2012 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing lilly 

Lilly UK has appointed Dr Jean-Michel Cosséry as the new managing director and VP of the UK Affiliate and the Northern Europe Geographic Hub.  

Cosséry will replace Ramona Sequeira who has been UK managing director for three years and will be taking a new role at Lilly’s Corporate Centre in Indianapolis, IN.

Cosséry joined Lilly in October after eight years at GE Healthcare, an $18 billion division of General Electric, where he was VP and chief marketing officer. Cosséry began his career as a researcher in neurosciences at the National Institutes of Health in America, after completing his PharmD and PhD Pharmacology in Paris, France.

Advertisement

Cosséry said: “I am delighted at this opportunity to join Lilly in this role because I share the company’s commitment to the patient and its dedication to innovation and research.  The next few years will be a challenging time for the UK pharmaceutical industry, but I have every confidence in Lilly’s ability to deliver on the promise of its pipeline.”

Andrew Hotchkiss, president of the Australia, Canada and Europe region added: “I am delighted to welcome Jean-Michel to Lilly, and believe his experience will be extremely beneficial as we prepare to launch our new products. We look forward to the leadership he will provide to our organisation and the patients.”

Related Content

NICE RECOMMENDS LILLY’S TIRZEPATIDE (MOUNJARO ®▼) FOR MANAGING OVERWEIGHT AND OBESITY IN FINAL DRAFT GUIDANCE

BASINGSTOKE, 5th December 2024 – Eli Lilly and Company announced today that the National Institute …

Eli Lilly front sign

Lilly’s COVID-19 drug has EUA revoked in favour of combination therapy

The FDA have revoked Emergency Use Authorization (EUA) of Eli Lilly’s bamlanivimab drug for the …

Eli Lilly building

Lilly’s ulcerative colitis treatment meets all key endpoints in Phase III trial

Eli Lilly’s mirikizumab treatment for ulcerative colitis (UC) patients has met the primary endpoints and …

The Gateway to Local Adoption Series

Latest content